Business Wire

CELONIS

29.11.2021 09:55:13 CET | Business Wire | Press release

Share
Celonis Accelerates its Process Mining and Execution Management Leadership in India

Celonis , the global leader in execution management, today announced that it will expand its process mining and execution management operations into India. Celonis believes the opportunity for customers, global system integrators (GSIs), business process outsourcing (BPO) providers, consultants, and academics is as big as the shift from on-prem to cloud.

As part of its execution management initiative in India, Celonis has committed to investing over $100 million dollars into the Indian process industry and expects to create more than 1,000 jobs. The expansion into India enables the world’s leading business process professionals and experts to unlock billions in new process and execution value for both their customers and within their own companies. The Celonis execution management initiative was launched at a multi-day press conference and partner ecosystem event in Bangalore, India.

The opportunity for process mining and execution management in India is immense. To provide context, Everest Group reports that the India BPO market for financial services alone has the potential to grow from $18 billion to $250 billion and currently represents nearly half of the world’s global outsourcing market. Furthermore, IDC estimates that the Indian IT & Business Services1 market will grow from $7 billion to $20 billion by 2025.

“Process mining should be at the core of digital transformation efforts and can play a critical role in helping to achieve greater scale, agility, and business value realization,” said Amardeep Modi, Vice President, Everest Group. “Celonis partners and customers in India will likely benefit greatly by having this new hub to assist, train, and promote best practices for the region. It would also help tap into India’s large talent base to fulfil the fast-growing demand for process mining skills globally.”

“India is undeniably a top global talent hub, and an IT and operations stronghold for Global 2000 enterprises,” said Reetika Fleming, Research Leader at HFS Research. “With this investment, Celonis is taking its technology right where it is needed. This will make it much easier for service providers to develop data-proficient workforces and presents an exciting opportunity for Indian students and consultants to work with process intelligence technologies.”

The Celonis India execution management initiative is designed around three strategic pillars that will enable the entire India process industry, and eventually every company across all sectors, to immediately adopt the most state of the art technologies into their core operations:

  • Execution Management Without Limits : The first pillar of this initiative is the rollout of the Celonis Execution Management Without Limits and the Celonis for BPO programs. These industry-first programs allow unlimited access to Celonis process mining and execution management technologies to any BPO, GSI and consulting professional.
  • Celonis Academy : The second pillar of this initiative is to provide free training and access to the best-in-class methods, processes, and programs for process mining and execution management to the entire India process consulting industry. Celonis plans to initially train more than 100,000 consultants, students and academics in India. This program is part of a global initiative where Celonis will train more than 1 million experts on process mining and execution management.
  • Celonis Center of Excellence : The third pillar is the new Celonis Center of Excellence (CoE) which will be the one-stop shop for customers, partners and service providers in India. The CoE combines partner enablement support, professional services and value advisory for customers, a dedicated product engineering team, and a customer support team to provide around-the-clock expertise and innovation.

“Every significant process innovation wave, from client server, to the internet, to the cloud has gone through the heart of the India business process industry,” said Bastian Nominacher, co-CEO and co-founder of Celonis. “Celonis is honored to help drive the next generational shift in process modernization in India by embedding our state-of-the-art process mining and execution management technologies into the world’s leading BPO, GCC, GSI and consulting firms.”

The Celonis partner ecosystem already includes many of the top tier consultancies, business process outsourcing (BPO) providers and consulting firms around the world, such as Accenture , Cognizant , Deloitte , EY, Firstsource , HCL, IBM , Infosys , KPMG , PWC , TCS , Tech Mahindra , Wipro , WNS and more. All of whom use the Celonis EMS to power digital and process transformation initiatives - for themselves and their clients.

“Celonis has removed all barriers for the entire India process ecosystem to put data to work and arm companies and organizations in every industry with our Execution Management System - which our customers call the ‘process brain’ for their businesses,” said Malhar Kamdar, Chief Customer Officer for Celonis and Executive leader for India. “Celonis has fully opened our platform with the goal of unlocking billions of value for users, enterprises and society. We are thrilled to bring the power of data execution to all our customers and partners in India.”

"Celonis is a key partner for Bosch worldwide, as we work together to bring our software offerings and process analytics to the next level, required to foster our ambition to become a data-driven, leading AIoT company,” said Jens Bockholt, VP Regional Manager at Bosch. “We are delighted that Celonis is continuing their global expansion with a new Center of Excellence in India and we look forward to further collaborating and leveraging Celonis to better serve our customers. We believe this will be mutually beneficial for both Celonis and the growing Indian marketplace.”

At their 2021 World Tour, Celonis announced a series of investments across each of the three key imperatives of the Celonis Execution Management System (EMS) - data, intelligence and action. This included the acquisition of real-time streaming data technology Lenses.io; the launch of the Celonis Execution Graph, that connects events from different processes across the company to identify bottlenecks; and a planned market defining partnership with ServiceNow .

“India’s market and talent base represents an unparalleled opportunity to capitalize on the global adoption of process mining and execution management at a massive scale,” said Anitha Scaria George, VP and Head of Celonis India. “As with every movement, there are companies who trailblaze and leapfrog the competition, and those who find themselves at the back of the parade. Celonis will train the next generation of execution management leaders to apply data, intelligence, and action to every process, in every business, in every industry.”

About Celonis

Celonis helps organizations to execute on their data. Powered by its market-leading process mining core, the Celonis Execution Management System provides a set of applications, a developer studio and platform capabilities for business executives and users to eliminate billions in corporate inefficiencies, provide better customer experience and reduce carbon emissions. Celonis has thousands of global customers and is headquartered in Munich, Germany and New York City, USA with 16 offices worldwide.

© 2021 Celonis SE. All rights reserved. Celonis and the Celonis “droplet” logo are trademarks or registered trademarks of Celonis SE in Germany and other jurisdictions. All other product and company names are trademarks or registered trademarks of their respective owners. 


1 tps://www.idc.com/getdoc.jsp?containerId=prAP48371321

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release

~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye